Zonagen Receives IRB Approval to Commence Phase III Study Of Androxal(TM) For The Treatment Of Testosterone Deficiency

Published: Jan 09, 2006

Zonagen, Inc. (Nasdaq:ZONA)(PCX:ZONA), a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders, today announced that the Company has received Investigational Review Board (IRB) approval for the start of its Phase III study of Androxal(TM), a once-a-day oral therapy for the treatment of testosterone deficiency resulting from a condition known as secondary hypogonadism. The 200 patient trial will be conducted in the U.S. under an existing U.S. Investigational New Drug application and will enroll patients at up to 20 clinical sites.

Back to news